Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research

[1]  L. Rider,et al.  Confusion Concerning Multiple Versions of the Childhood Myositis Assessment Scale , 2014, Arthritis care & research.

[2]  I. Lundberg,et al.  Registries in idiopathic inflammatory myopathies , 2013, Current opinion in rheumatology.

[3]  C. Sandborg,et al.  Using Registries to Identify Adverse Events in Rheumatic Diseases , 2013, Pediatrics.

[4]  A. Ravelli,et al.  Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. , 2013, Clinical and experimental rheumatology.

[5]  L. Wedderburn,et al.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? , 2013, Arthritis Research & Therapy.

[6]  N. Wulffraat,et al.  Time to share , 2013, Pediatric Rheumatology.

[7]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[8]  N. Wulffraat,et al.  The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis , 2012, Annals of the rheumatic diseases.

[9]  Keith Marsolo,et al.  An i2b2-based, generalizable, open source, self-scaling chronic disease registry , 2012, J. Am. Medical Informatics Assoc..

[10]  N. Wulffraat,et al.  A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. , 2012, Arthritis and rheumatism.

[11]  A. Reed,et al.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis , 2011, Nature Reviews Rheumatology.

[12]  L. Wedderburn,et al.  Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM) , 2011, Pediatric Rheumatology Online Journal.

[13]  L. Wedderburn,et al.  Comparison of data from the juvenile dermatomyositis national (UK & Ireland) cohort biomarker study and repository for idiopathic inflammatory myopathies with a survey of current practice throughout the UK and Ireland , 2011, Pediatric Rheumatology Online Journal.

[14]  H. Alexanderson,et al.  Patient Preference Assessment Reveals Disease Aspects Not Covered by Recommended Outcomes in Polymyositis and Dermatomyositis , 2011, ISRN rheumatology.

[15]  N. Wulffraat,et al.  The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis , 2010, Arthritis care & research.

[16]  L. Wedderburn,et al.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies , 2010, Rheumatology.

[17]  P. Mathiesen,et al.  Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. , 2010, Clinical and experimental rheumatology.

[18]  B. Lie,et al.  Long‐term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case–control study , 2010, Arthritis care & research.

[19]  D. Moher,et al.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders , 2010, Arthritis care & research.

[20]  B. Feldman,et al.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference , 2010, Arthritis care & research.

[21]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[22]  F. Miller,et al.  Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. , 2009, Dermatology online journal.

[23]  B. Feldman,et al.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.

[24]  Michel Fischbach,et al.  The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. , 2008, Arthritis and rheumatism.

[25]  W. Ollier,et al.  HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. , 2007, Rheumatology.

[26]  B. Feldman,et al.  International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. , 2005, Arthritis and rheumatism.

[27]  P. Lachenbruch,et al.  International consensus on preliminary definitions of improvement in adult and juvenile myositis. , 2004, Arthritis and rheumatism.

[28]  W. Kuis,et al.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. , 2003, Rheumatology.

[29]  B. Santmyire-Rosenberger,et al.  Skin involvement in dermatomyositis , 2003, Current opinion in rheumatology.

[30]  A. Dyer,et al.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. , 2003, Arthritis and rheumatism.

[31]  P. Lachenbruch,et al.  Defining Clinical Improvement in Adult and Juvenile Myositis. , 2003, The Journal of rheumatology.

[32]  S. Sawhney,et al.  The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). , 2001, Clinical and experimental rheumatology.

[33]  P. Lachenbruch,et al.  Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. , 2001, The Journal of rheumatology.

[34]  L. Pachman,et al.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. , 1999, Arthritis and rheumatism.

[35]  D. Symmons,et al.  The incidence of juvenile dermatomyositis: results from a nation-wide study. , 1995, British journal of rheumatology.

[36]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[37]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[38]  M. Tesher.  Pediatric Rheumatology. , 2015, Pediatric annals.

[39]  Andreas Ringman Uggla,et al.  DEPARTMENT OF WOMEN’S AND CHILDREN’S HEALTH DIVISION OF PEDIATRIC SURGERY KAROLINSKA INSTITUTET , 2010 .

[40]  加藤 美穂子.  Great Ormond Street Hospital を訪れて , 2007 .